dm+d

Unassigned

New Medicines

Locally advanced, unresectable non-small cell lung cancer (NSCLC) - with durvalumab in patients whose disease has not progressed following chemoradiation therapy

Information

New molecular entity
Gilead Sciences
Arcus and Gilead

Development and Regulatory status

None
Phase III Clinical Trials
None

Category

A fully humanised monoclonal antibody that binds to human T-cell immuno-receptor with Ig and ITIM domains (TIGIT), an inhibitory receptor expressed on NK and CD8+ T cells, and inhibits the ability of CD155 and TIGIT to interact
There are around 48,000 new lung cancer cases and 35,000 deaths from lung cancer in the UK every year. The majority of lung cancers are diagnosed at an advanced stage, when the cancer has spread to lymph nodes and other organs in the chest (locally advanced disease; stage III) or to other parts of the body (metastatic disease; stage IV). Up to 85% of lung cancers are NSCLC [1].
Locally advanced, unresectable non-small cell lung cancer (NSCLC) - with durvalumab in patients whose disease has not progressed following chemoradiation therapy
Intravenous infusion